An improved gas chromatography assay for topiramate monitoring in pediatric patients

Therapeutic Drug Monitoring

Volumn 22, Issue 2, 2000, Pages 195-201

  Tang, Peter H ^a   Miles, Michael V ^a   Glauser, Tracy A ^a   Coletta, Lauren ^a   Doughman, Nancy ^a   Doose, Dennis ^b   Frey, Mary ^a   DeGrauw, Antonius ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b Ortho McNeil Pharmaceutical Incorporated   (United States)

Author keywords

Gas chromatography; Immunoassay; Microanalysis; Therapeutic drug monitoring; Topiramate

Indexed keywords

TOPIRAMATE;

ADOLESCENT; ARTICLE; CAPILLARY GAS CHROMATOGRAPHY; CHILD; CONTROLLED STUDY; DIAGNOSTIC VALUE; DRUG CROSS REACTIVITY; DRUG DETERMINATION; DRUG MONITORING; DRUG RETENTION; DRUG SPECIFICITY; FLUORESCENCE POLARIZATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

ANTICONVULSANTS; CHILD; CHROMATOGRAPHY, GAS; DRUG MONITORING; FLUORESCENCE POLARIZATION; FRUCTOSE; HUMANS; IMMUNOASSAY;

EID: 0034074251     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200004000-00010     Document Type: Article

References (13)

1. Faught E, Wilder BJ, Ramsay RE, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Neurology 1996;46:1684-1690.
2. Privitera M, Fincham R, Penry J, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1,000-mg daily dosages. Neurology 1996;46:1678-1683.
3. Tassinari CA, Michelucci R, Chauvel P, et al. Double-blind, placebo-controlled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy. Epilepsia 1996;37:763-768.
4. Ben-Menachem E, Henriksen O, Dam M, et al. Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures. Epilepsia 1996;37:539-543.
5. Glauser TA. Topiramate. Semin Pediatr Neurol 1997;4:34-42.
6. Holland ML, Uetz JA, Ng KT. Automated capillary gas chromatographic assay using flame ionization detection for the determination of topiramate in plasma. J Chrom 1988;433:276-281.
7. Innofluor Topiramate Assay System [manual]. Portland, OR: OXIS International, Inc; 1997:1-4.
8. Masucci JA, Ortegon ME, Jones WJ, Shank RP, Caldwell GW. In vivo microdialysis and liquid chromatography/thermospray mass spectrometry of the novel anticonvulsant 2,3:4,5-bis-o-(1-methylethylidene)-(-d-fructopyranose sulfamate (topiramate) in rat brain fluid. J Mass Spec 1998;33:85-88.
9. Riffitts JM, Gisclon LG, Stubbs RJ, Palmer ME. A capillary gas chromatographic assay with nitrogen phosphorus detection for the quantification of topiramate in human plasma, urine and whole blood. J Pharm Biomed Anal 1999;19:363-371.
10. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1: 307-10.
11. Wu WN, Heebner JB, Streeter AJ, et al. Evaluation of the absorption, excretion, pharmacokinetics and metabolism of the anticonvulsant topiramate in healthy men. Pharm Res 1994;11(suppl): S336.
12. Bourgeois BFD. Important pharmacokinetic properties of antiepileptic drugs. Epilepsia 1995;36(suppl)5:S1-7.
13. Gisclon LG, Riffits JM, Sica DA, Gehr T, Ruddley J. The pharmacokinetics of topiramate in subjects with renal impairment as compared to matched subjects with normal renal function. Pharm Res 1993;10 (suppl):S397.